> For the complete documentation index, see [llms.txt](https://www.brexatlas.org/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://www.brexatlas.org/bre-001/bre-037.md).
# BRE 037
## TTFields, Chemotherapy, and Clinical Translation in Mesothelioma
**Clinical Cancer Name:** Unresectable Pleural Mesothelioma\
**Common Cancer Name:** Mesothelioma / Cancer of the Lung Lining
## Source
Ceresoli, G. L., & Gianoncelli, L. (2025).
*Tumor Treating Fields (TTFields) Therapy in Unresectable Pleural Mesothelioma: Overview of Efficacy, Safety, and Future Outlook.*
*Current Treatment Options in Oncology, 26, 398–414.*
***
## BRS Score
**BRS:** 9.1 / 10\
**STEMD:** S10 / T10 / E9 / M8 / D9\
**External Evidence Level:** High clinical + translational review evidence
### Score Interpretation
BRE-037 receives a high BRS because it connects TTFields to a clinical mesothelioma treatment context, including thoracic delivery, chemotherapy combination, safety, survival, and future optimization. Its strongest value is clinical translation.
***
## Entry Summary
BRE-037 asks a practical clinical question:
Can Tumor Treating Fields be used with chemotherapy for mesothelioma that cannot be surgically removed?
This review focuses on unresectable pleural mesothelioma.
In simple language:
Mesothelioma is a cancer that often forms in the lining around the lungs. When it cannot be removed by surgery, treatment options are limited. BRE-037 shows that TTFields has been studied with chemotherapy as a clinical strategy for this cancer.
***
## What BREXAtlas Found
BREXAtlas identifies this clinical combination chain:
TTFields\
+\
Pemetrexed / platinum chemotherapy\
↓\
Amplified tumor stress\
↓\
Enhanced apoptosis\
↓\
Improved mesothelioma control
The main mechanism chain is:
TTFields\
↓\
Mitotic spindle disruption\
↓\
Cytokinetic destabilization\
↓\
Abnormal daughter-cell formation\
↓\
Tumor-cell death
The immune chain is:
TTFields\
↓\
Immunogenic cell death\
↓\
Dendritic-cell activation\
↓\
Adaptive immune recruitment\
↓\
Antitumor immune response
This makes BRE-037 important because it shows TTFields as a clinical system, not only a laboratory mechanism.
***
## Questions This BRE Helps Answer
What is pleural mesothelioma?
Pleural mesothelioma is cancer of the lining around the lungs.
It is often aggressive and difficult to treat, especially when surgery is not possible.
What BREXAtlas found:\
BRE-037 focuses on unresectable pleural mesothelioma and thoracic TTFields delivery.
What frequency is used?
What BREXAtlas found:\
BRE-037 identifies 150 kHz as the TTFields frequency used in mesothelioma systems, delivered through the thoracic NovoTTF-100L system with continuous application recommended at more than 18 hours per day.
What clinical result matters most?
What BREXAtlas found:\
The extraction reports that the STELLAR trial median overall survival reached 18.2 months with TTFields combined with pemetrexed and platinum chemotherapy.
This makes BRE-037 a major clinical translation entry.
What side effects were most associated with TTFields?
What BREXAtlas found:\
TTFields-related toxicity was primarily mild-to-moderate skin irritation.
This matters because clinical translation depends not only on efficacy, but also tolerability.
***
## Study Classification
| Category | Classification |
| --------------------------------------- | ------------------------------------------------------------------------------------ |
| Study Type | Clinical translational review / mesothelioma TTFields systems review |
| Tissue Category | Pleural mesothelioma; thoracic oncology |
| Common Cancer Name | Mesothelioma / cancer of the lung lining |
| Models / Evidence Systems | Mesothelioma cell systems; orthotopic thoracic tumor systems; STELLAR trial patients |
| Frequency | 150 kHz |
| Delivery System | Thoracic TTFields delivery; NovoTTF-100L |
| Application | Continuous; >18 h/day recommended |
| Combination | Pemetrexed + platinum chemotherapy |
| Direct TTFields Evidence | Yes, clinical review-supported |
| Suitable for Clinical Translation Index | Yes |
| Suitable for Mesothelioma Index | Yes |
| Suitable for Frequency Index | Yes |
***
## Mechanisms
**MEC-001: Mitotic Disruption**
TTFields disrupt mitotic spindle processes and tumor-cell division.
**MEC-003: DNA Repair Interference**
TTFields may affect DNA repair pathways.
**MEC-004: Immunogenic Cell Death**
TTFields may help trigger immunogenic tumor-cell death.
**MEC-009: Immune Modulation**
TTFields may support immune activation and adaptive immune recruitment.
**MEC-016: Septin Mislocalization**
TTFields may disturb septin organization during cell division.
**MEC-022: Cytokinetic Furrow Destabilization**
TTFields may disrupt the final separation stage of dividing tumor cells.
**MEC-048: TTFields-Induced Immune Recruitment**
TTFields may activate immune signaling that supports antitumor immune response.
**MEC-092: Thoracic TTFields Delivery Systems**
BRE-037 introduces thoracic delivery as a distinct clinical TTFields application problem.
***
## Discoveries
**DISC-005: Combination Therapy Amplification**
BRE-037 supports TTFields as a chemotherapy amplifier in mesothelioma systems.
**DISC-021: Clinical Systems-Level TTFields Integration**
BRE-037 strengthens clinical TTFields integration beyond glioblastoma.
**DISC-023: Mesothelioma TTFields Translation**
BREXAtlas identifies this as a major discovery:
TTFields has moved into clinical translation for unresectable pleural mesothelioma through thoracic delivery and chemotherapy combination.
***
## Connections to Other BRE Entries
### Connected to BRE-036
BRE-036 focused on glioblastoma clinical TTFields translation.
BRE-037 extends the applied TTFields clinical framework into mesothelioma.
### Connected to BRE-014, BRE-015, and BRE-016
BRE-014 showed mitotic disruption.
BRE-015 showed septin mislocalization.
BRE-016 showed cytokinetic furrow destabilization.
BRE-037 applies those mechanisms in a clinical mesothelioma translation context.
### Connected to BRE-005
BRE-005 introduced immune activation through TTFields.
BRE-037 includes immunogenic cell death, dendritic-cell activation, adaptive immune recruitment, and antitumor immune response.
### Connected to BRE-020
BRE-020 described TTFields combination therapy with radiation and chemotherapy.
BRE-037 provides clinical mesothelioma context for TTFields plus pemetrexed/platinum chemotherapy.
### Connected to BRE-021
BRE-021 emphasized frequency optimization and field delivery.
BRE-037 contributes a mesothelioma-specific clinical frequency and delivery system: 150 kHz thoracic TTFields.
***
## Research Gaps Identified
**RG-183: Mesothelioma Patient Selection Gap**
More research is needed to determine which mesothelioma patients are most likely to benefit from TTFields.
**RG-184: Treatment Sequencing Gap**
Future trials should clarify how TTFields should be sequenced with chemotherapy and immunotherapy.
**RG-185: Thoracic Delivery Optimization Gap**
More work is needed to optimize array placement, field distribution, and thoracic anatomy modeling.
**RG-186: Long-Term Outcome Prediction Gap**
More studies are needed to identify biomarkers predicting long-term benefit.
**RG-187: Randomized Controlled Trial Gap**
Additional randomized controlled trials are needed to strengthen clinical certainty.
***
## Scientific Caution
This review integrates clinical and mechanistic TTFields evidence for pleural mesothelioma. Additional randomized controlled trials remain necessary to optimize patient selection, treatment sequencing, and long-term outcome prediction.
***
## Why This Entry Matters
For researchers, BRE-037 shows TTFields moving from brain cancer into thoracic oncology.
For patients and families, the simple idea is this:
For mesothelioma that cannot be removed by surgery, TTFields has been studied with chemotherapy. The evidence suggests clinical promise, but more trials are still needed to know who benefits most and how to optimize treatment.
***
## Entry Conclusion
BRE-037 expands the BREXAtlas clinical translation section.
BRE-036 established TTFields as a clinical systems platform in glioblastoma.
BRE-037 extends that platform into unresectable pleural mesothelioma using 150 kHz thoracic delivery and chemotherapy combination.
The central question emerging from this entry is:
Can TTFields become a clinically optimized thoracic oncology platform for unresectable mesothelioma?
For BREXAtlas, BRE-037 is essential because it shows TTFields crossing from one major clinical cancer context into another.
---
# Agent Instructions
This documentation is published with GitBook. GitBook is the documentation platform designed so that both humans and AI agents can read, navigate, and reason over technical content effectively. Learn more at gitbook.com.
## Querying This Documentation
If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question.
Perform an HTTP GET request on the current page URL with the `ask` query parameter, and the optional `goal` query parameter:
```
GET https://www.brexatlas.org/bre-001/bre-037.md?ask=&goal=
```
`ask` is the immediate question: it should be specific, self-contained, and written in natural language.
`goal` is optional and describes the broader end goal you are ultimately trying to accomplish on behalf of the user. GitBook uses it to tailor the answer towards what is most useful for that goal.
The response will contain a direct answer to the question and relevant excerpts and sources from the documentation.
Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.